{"id":376956,"date":"2010-03-01T18:00:36","date_gmt":"2010-03-01T23:00:36","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=65927"},"modified":"2010-03-01T18:00:36","modified_gmt":"2010-03-01T23:00:36","slug":"zafgen-grabs-8-1m-more-in-b-round","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/376956","title":{"rendered":"Zafgen Grabs $8.1M More in B Round"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Life-Sciences\/\">Life Sciences<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/VC\/\">VC<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a><\/div>\n<p>\t\t<strong>Ryan McBride wrote:<\/strong><\/p>\n<p>Zafgen, a Cambridge, MA-based startup focused on new obesity treatments, has raised $8.1 million in a third closing of its $28 million Series B round, a company spokeswoman confirmed this afternoon. The funding was revealed today in this SEC <a href=\"http:\/\/www.sec.gov\/Archives\/edgar\/data\/1374690\/000137469010000003\/xslFormDX01\/primary_doc.xml\">filing<\/a>. The company, which has now raised $30 million, received the fresh capital from previous backers Third Rock Ventures in Boston and Atlas Venture in Waltham, MA. <a href=\"http:\/\/www.xconomy.com\/boston\/2010\/02\/08\/zafgens-mysterious-weight-loss-drug-advances-into-first-trial-for-obese-women\/\">Zafgen CEO Tom Hughes told Luke earlier this year that the firm isn&#8217;t exactly sure how its drugs work<\/a>, after a study showed that its earlier hypothesis that its molecules cut off the blood supply to fat tissues turned out be wrong.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/boston\/2010\/03\/01\/zafgen-grabs-8-1m-more-in-b-round\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Zafgen%20Grabs%20$8.1M%20More%20in%20B%20Round%20http:\/\/xconomy.com\/?p=65927\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/boston\/2010\/03\/01\/zafgen-grabs-8-1m-more-in-b-round\/&#038;t=Zafgen%20Grabs%20$8.1M%20More%20in%20B%20Round\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/boston\/2010\/03\/01\/zafgen-grabs-8-1m-more-in-b-round\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Zafgen+Grabs+%248.1M+More+in+B+Round&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fboston%2F2010%2F03%2F01%2Fzafgen-grabs-8-1m-more-in-b-round%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=9498b9a484c9d05e87216c787cb98ed9&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=9498b9a484c9d05e87216c787cb98ed9&#038;p=1\"\/><\/a><br \/>\n<img loading=\"lazy\" decoding=\"async\" alt=\"\" height=\"0\" width=\"0\" border=\"0\" style=\"display:none\" src=\"http:\/\/a.rfihub.com\/eus.gif?eui=2218\"\/><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/wAAYgXtizIsjmoVqFg_BrCGqUMs\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/wAAYgXtizIsjmoVqFg_BrCGqUMs\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/wAAYgXtizIsjmoVqFg_BrCGqUMs\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/wAAYgXtizIsjmoVqFg_BrCGqUMs\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/ncwsuqSOX5Q\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Life Sciences, VC, deals Ryan McBride wrote: Zafgen, a Cambridge, MA-based startup focused on new obesity treatments, has raised $8.1 million in a third closing of its $28 million Series B round, a company spokeswoman confirmed this afternoon. The funding was revealed today in this SEC filing. The company, which has now raised $30 million, [&hellip;]<\/p>\n","protected":false},"author":2829,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-376956","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/376956","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2829"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=376956"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/376956\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=376956"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=376956"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=376956"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}